NASDAQ$BCPC

Balchem Corporation · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Balchem reported a growth in net sales and adjusted EBITDA, but a decrease in GAAP net earnings compared to the prior year quarter.

Balchem Corporation reported a 9.1% increase in fourth-quarter net sales, reaching $232.5 million. Adjusted EBITDA rose by 14.6% to $52.3 million, while GAAP net earnings decreased by 14.2% to $21.4 million. The company's adjusted earnings per share increased to $0.94.

  • Net sales increased by 9.1% to $232.5 million due to growth in Human Nutrition & Health and Specialty Products segments.
  • Adjusted EBITDA increased by 14.6% to $52.3 million.
  • GAAP net earnings decreased by 14.2% to $21.4 million, resulting in GAAP earnings per share of $0.66.
  • Adjusted net earnings increased by 9.1% to $30.3 million, resulting in adjusted earnings per share of $0.94.

Headline financials

Total Revenue

$233M

Previous: $799M-70.9%
EPS (adj)

$0.67

Previous: $0.77-13.0%
Adjusted EBITDA

$52.3M

Previous: $45.6M+14.6%
Capital Expenditures

$14.1M

Previous: $14.6M-3.0%
Free Cash Flow

$27.5M

Previous: $30.5M-9.8%
Net Income

$21.4M

Previous: $24.9M-14.2%
Operating Income

$33.3M

Previous: $33.8M-1.5%
Gross Profit

$68.6M

Previous: $64.1M+7.1%
Cash & Equivalents

$66.6M

Previous: $103M-35.5%
Total Assets

$1.62B

Previous: $1.2B+35.5%
Stock-Based Comp

$3.39M

Previous: $1.99M+69.9%

Revenue & EPS history

Balchem · Revenue · Quarterly

$233M

Q4 2022-70.9%vs Q4 2021
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Balchem · $227M total across 3 segments · Q4 2022

  • Human Nutrition & Health
    $130M+12.9%
  • Animal Nutrition & Health
    $64.8M-0.3%
  • Specialty Products
    $31.8M+16.2%

Forward guidance

Balchem is well-positioned to drive continued growth and progress on its strategic growth initiatives while managing through the new challenges expected within this dynamic global market environment in 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+0.0%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.9%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+25.0%

Q1 2014

Best reaction

-16.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.8%-7.0%-9.7%
Q4 2025-2.3%+2.6%-7.4%
Q3 2025+4.1%+3.9%+1.3%
Q1 2025-2.6%-1.5%+4.8%
Q4 2024+1.5%+7.0%-0.1%
Q3 2024+2.8%+1.6%+9.8%
Q2 2024+3.9%+1.5%-1.2%
Q1 2024-1.8%-3.0%-8.8%
Q4 2023+7.4%+5.0%+6.8%
Q3 2023-5.0%-4.1%+1.1%
Q2 2023+4.8%+5.0%+7.1%
Q1 2023+1.7%+0.5%+5.2%
Q4 2022-2.0%-0.2%-7.7%
Q3 2022-0.6%-0.5%+5.4%
Q2 2022-5.2%-6.6%+2.3%
Q1 2022+1.6%-0.9%-10.5%
Q4 2021+1.0%-0.7%+1.2%
Q3 2021-0.8%+2.3%+7.9%
Q2 2021-0.8%-2.5%+2.7%
Q1 2021-0.2%-0.1%+0.5%
Q4 2020+5.4%+6.4%+10.7%
Q3 2020-1.7%-0.5%+3.3%
Q2 2020+4.6%+4.7%+0.3%
Q1 2020-5.4%-3.9%-9.3%
Q4 2019-10.7%-13.3%-15.9%
Q3 2019+2.9%+1.2%-0.8%
Q2 2019-16.3%-15.9%-13.5%
Q1 2019+1.1%+4.0%+9.4%
Q4 2018+8.0%+12.4%+10.7%
Q3 2018-4.9%-4.9%-13.7%
Q2 2018+1.1%+1.3%+10.1%
Q1 2018-1.3%+2.2%+7.9%
Q4 2017+2.3%+5.9%+8.6%
Q3 2017+1.0%-0.7%+1.3%
Q2 2017-2.6%-3.9%-1.8%
Q1 2017-3.3%-5.3%-1.8%
Q4 2016+5.2%+2.2%-2.5%
Q3 2016-4.5%+0.8%+12.3%
Q2 2016+1.3%+2.0%+8.7%
Q1 2016+0.3%
Q4 2015-0.4%
Q3 2015-2.0%
Q2 2015+5.2%
Q1 2015-0.5%
Q4 2014-3.4%
Q3 2014+6.7%
Q2 2014+2.5%
Q1 2014+25.0%
Q4 2013+0.4%
Q3 2013-4.9%
Q2 2013+1.3%
Q1 2013-2.3%
Q4 2012+0.8%
Q3 2012-10.5%
Q2 2012+5.9%
Q1 2011+2.1%
Q4 2011+2.1%
Q1 2012+2.4%
Q1 2010-4.1%
Q4 2009-4.1%
Q3 2010-3.2%
Q3 2011-3.2%
Q2 2011+1.0%
Q4 2010+1.0%
Q2 2010+1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro